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ABSTRACT 
Chronic liver disease is an increasing cause of global morbidity and mortality. The popular 
belief is that liver disease is caused mainly by alcoholic liver disease or viral hepatitis. 
However, the most common cause of chronic liver disease today is non-alcoholic fatty liver 
disease (NAFLD), which is associated with obesity and insulin resistance rather than alcohol. 
NAFLD is considered to become the most common cause for need of liver transplantation in 
the coming years. Today, the most common cause of liver transplantation in Sweden is 
primary sclerosing cholangitis (PSC) - a rare but very serious disease of the bile ducts that 
become inflamed and obliterated, and is associated with a high risk of development of 
cholangiocarcinoma.  
The role of concurrent use of alcohol in NAFLD and PSC is controversial. Part of this thesis 
explores the effect of alcohol on the degree of liver damage in these two diseases. We found 
that a low consumption of alcohol, around one unit per day, is not associated with a higher 
stage of fibrosis in the liver in PSC and should be safe in these patients. For NAFLD, we 
found that a low to moderate consumption of alcohol was associated with a lower risk for a 
higher fibrosis stage, up to thirteen units of alcohol per week. However, patients who had 
biochemical evidence of high alcohol consumption had a higher risk of more severe liver 
damage. This is well in line with other studies and indicates a J-formed risk profile for 
alcohol consumption in NAFLD.  
In another part of the thesis we studied the long-term risk of having fat accumulation in the 
liver and if overweight per se can predict development of severe liver disease. We found that 
the strongest histological marker for disease-specific mortality in NAFLD after a follow-up 
of in mean 26 years was the stage of fibrosis, and found no excess mortality in patients with 
signs of inflammation in the liver after adjustment for the stage of fibrosis. The risk of being 
overweight was studied in close to 45.000 men in their late adolescence who were conscribed 
to military service in 1969-1970 after adjustment of potential confounders, such as alcohol 
consumption. Body mass index (BMI) was found to be an independent predictor of 
development of severe liver disease after a mean follow-up of 39 years. 
Taken together, this thesis indicates that a low to moderate consumption of alcohol is safe in 
PSC and possibly protective in NAFLD. Furthermore, we found that the strongest predictor 
of disease-specific mortality in NAFLD is the stage of fibrosis, which can have implications 
for the design of endpoints in future clinical studies. Also, the finding that overweight per se 
is a predictor for development of severe liver disease is important for public health decision-
making.  
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1 INTRODUCTION 
While there has been a tremendous success for modern medicine in the latest 30 years, with 
for instance a reduction of mortality in cardiovascular disease (CVD) of more than 25 % (1), 
there has been little progress in mortality in liver disease. For instance, recent data from the 
UK indicates that liver disease is the only increasing cause of death with a 500 % increase in 
the standardized mortality ratio since 1970, depicted in figure 1 (2).   
Liver diseases are common causes of mortality and morbidity worldwide. There are many 
different diseases that can lead to liver damage. Damage to the liver generally results in 
formation of scar tissue, fibrosis. Fibrosis can be progressive over the years, and the end 
result is cirrhosis.  In rural settings viral hepatitis dominates the disease spectrum, with for 
instance a prevalence of chronic hepatitis C virus (HCV) in Egypt of up to 15 % while the 
prevalence in Sweden is estimated at around 0.3 % (3, 4). In North America and Europe, 
alcohol is often considered the most common cause of chronic liver disease. However, non-
alcoholic fatty liver disease (NAFLD) is highly more prevalent than alcohol induced liver 
disease even on a global scale. The prevalence of NAFLD is estimated to be as high as 46% 
in some populations and is more closely discussed below (5, 6).  
 
Figure 1. Standardized mortality ratios for causes of death in the UK. From Williams et al, 
Lancet 2014;384:1953-1997. Published with permission. 
This indicates that liver disease is one of the major challenges for modern medicine as well as 
for health care politicians in the years ahead.  
1.1 NON-ALCOHOLIC FATTY LIVER DISEASE 
The prevalence of overweight and obesity has risen dramatically in the world during the last 
30 years. For instance, the prevalence of obesity in the US has increased from 13% in 1972 to 
almost 35% in 2012 and is estimated to account for up to 10% of total health expenditure (2). 
A figure of the increasing trend of obesity in OECD countries is presented in figure 2 (7).  
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Figure 2. Prevalence of obesity in selected OECD countries from 1972 – 2012. Obesity 
update © OECD 2014 (7). 
Coupled to this epidemic of overweight and obesity, NAFLD has emerged as the most 
prevalent liver disease in the world (5, 8). This disease is now considered to be the hepatic 
manifestation of the metabolic syndrome, and is heavily associated with obesity and insulin 
resistance. 
The prevalence of NAFLD depends partly on the studied population and the prevalence of 
overweight and obesity, as well as on the diagnostic method used. In the U.S., prevalence has 
been estimated to 46% using liver biopsy (6) but only 11% by using levels of serum liver 
enzymes as marker for NAFLD (9). Also, genetic predisposition to NAFLD is likely. For 
instance, persons with an Asian background develop NAFLD at lower BMI levels than 
Caucasians do (5). The prevalence of NAFLD in Europe is estimated to around 2-44% 
depending on the studied population (10). The global prevalence of NAFLD has recently 
been estimated to around 25% (11). 
A subgroup of around 10-20% of patients with NAFLD develops inflammation in the liver, 
named non-alcoholic steatohepatitis (NASH) (12, 13). This aspect of the NAFLD disease 
spectrum can at present only be diagnosed using liver biopsy. Patients without NASH are 
considered to have non-alcoholic fatty liver (NAFL). The traditional hypothesis was that only 
patients with NASH are at risk for progressive fibrosis, with 10-25% of NASH patients at 
risk for development of cirrhosis and/or hepatocellular carcinoma (HCC) (14-17). However, 
it is only logical that patients without NASH at early stages of the NAFLD disease spectrum 
can later go on to develop NASH and progressive fibrosis, which has recently been proven 
  3 
(18-20). This puts even more persons at risk for potential liver damage and makes it harder to 
define which part of the population that should be screened for more advanced stages of 
disease or followed clinically.  
The pathophysiology behind NAFLD and NASH is highly complex, and why some persons 
develop NASH is in particular poorly understood. In the setting of insulin resistance, lipolysis 
of adipose tissue is increased, leading to an increase in free fatty acid flow through the portal 
vein to the liver. Also, hepatic de novo lipogenesis is up-regulated in insulin resistance, and 
patients with NAFLD often have an increased dietary intake of lipids. These combined 
effects all contribute to hepatic steatosis when free fatty acids are esterified into triglycerides 
(21-23). Interestingly, steatosis per se is not necessarily dangerous. In an elegant experiment, 
Yamaguchi et al blocked the final step in triglyceride formation in mice by blocking 
diacylglycerol acyltransferase 2 (DGAT2) through antisense nucleotide treatment. The result 
was a reduction in hepatic steatosis, but a marked increase in inflammation and fibrosis (24), 
indicating that hepatic steatosis might actually be a mechanism protecting hepatocytes from 
lipotoxicity induced by oxidation of free fatty acids. However, the exact pathophysiology 
behind development of NASH remains shrouded. The two-hit hypothesis was established by 
Day in 1998 (25). According to this, hepatic steatosis is the first “hit”, sensitizing hepatocytes 
to further injury by inflammation, oxidative stress and mitochondrial dysfunction. This theory 
has since then evolved, and currently, a “multiple-hit” hypothesis has been perceived as more 
likely (22, 23). This includes contribution from genetic susceptibility, gut-derived endotoxins, 
pro-inflammatory cytokines and oxidative stress, and is beyond the scope of the introduction 
in this thesis. A brief summary of the pathophysiology of NAFLD and NASH is presented in 
figure 3. 
To date, there is no effective medical treatment for either NAFLD or NASH. Lifestyle 
changes, if successful, on the other hand have a dramatic positive effect on almost all aspects 
of the disease (26). In a recent study from Cuba of the impact of weight loss on NASH, 97% 
of patients who lost more than ten percent of total body weight during one year cleared all the 
fat from the liver. A reduction in inflammation and even in fibrosis was also seen. However, a 
weight loss of more than ten percent could only been seen in about ten percent of the included 
patients (27). Other lifestyle changes that have some level of evidence is a reduction in intake 
of fructose, usually derived from consumption soft drinks that are sweetened with high-
fructose corn syrup, which has been implicated as a risk factor for accumulation of fat and 
fibrosis in the liver (28, 29). Also, coffee intake has been suggested to be protective both in 
NAFLD and in other liver diseases (30, 31), possibly by inhibiting the activation of hepatic 
stellate cells (32). A reduction in the risk of development of HCC has also been observed (33-
35). Provided that no relative contraindication to coffee consumption such as an uncontrolled 
high blood pressure exists, some researchers advocate an intake of 2-3 cups per day.  
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Figure 3. Pathophysiology of NAFLD and NASH. From Than et al. A concise review of non-
alcoholic fatty liver disease. Atherosclerosis 2015;239:192-202. Published with permission.  
1.1.1 NASH diagnosis 
As stated above, the clinical entity of NASH can currently only be diagnosed through liver 
biopsy. The hallmark of NAFLD is obviously hepatic steatosis, and at least 5% of 
hepatocytes have to be steatotic for the pathologist to be able to set the NAFLD diagnosis 
(36). Other hallmarks of NAFLD include swelling of apoptotic hepatocytes, called 
ballooning, and lobular inflammation as well as fibrosis. Typical histopathological findings 
are presented in figure 4.  
During the years, several scoring systems for the histological severity of NAFLD have been 
proposed. Brunt et al in 1999 proposed a scoring system for the severity of NASH, which is 
presented in table 1. However, this system was not intended to separate cases with NASH 
from cases without, and is currently less used (37).  
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Grade of steatohepatitis Staging fibrosis 
Grade Steatosis Ballooning Lobular 
inflammation 
Portal 
inflammation 
Stage Fibrosis 
Mild Involves up 
to 2/3rds 
Occasional, 
zone 3 
Scattered, 
mild acute 
and chronic 
None or mild 0 None 
Moderate Any degree Obvious, 
zone 3 
Mild, 
associated 
with 
ballooning 
Mild to 
moderate 
1 Zone 3 
perisinusoidal 
fibrosis only 
Severe Typically 
more than 
2/3rds 
Marked,  
mainly zone 
3 
Mild to 
moderate 
Mild to 
moderate 
2 Zone 3 
perisinusoidal 
fibrosis and 
periportal 
fibrosis 
3 Bridging 
fibrosis 
4 Cirrhosis 
Table 1. Brunt scoring system for NASH severity.  
 
In 2005, the American NASH clinical research network (NASH CRN) proposed a new 
grading system for the histological severity of NAFLD, which was named the NAFLD 
activity score (NAS). In this score, steatosis is graded on a semi-quantitative scale as 0-3, 
lobular inflammation as 0-3 and ballooning as 0-2, yielding a total score of 0-8 (38). The 
NAS was constructed as being an endpoint in clinical trials, but was quickly adopted as a 
mean to diagnose NASH and differentiate it from NAFL. This was however not intended, 
and the authors have clearly defined this (39). The NAS has also been criticized for not 
including fibrosis in the score, as well as overstating the importance of steatosis in the 
algorithm.  
A more recent scoring system is the SAF score, for Steatosis Activity Fibrosis (40, 41). In 
this system, steatosis is required for inclusion in the algorithm at all and is scored as 0-3. 
Biopsies are then graded for ballooning on a 0-2 scale and lobular inflammation on a 0-2 
scale. A score of at least one for both steatosis, ballooning and lobular inflammation is 
required for NASH diagnosis. A figure of the diagnostic algorithm of NASH according to the 
SAF scoring system is presented in figure 5.  
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Figure 4. Histopathology of NAFLD. The picture depicts some hallmarks of the NAFLD entity. In A is 
seen the classical ballooning of two hepatocytes (arrows). In B, macro- and microvesicular steatosis can easily 
be seen. In C, small infiltrates of inflammatory cells are seen in the liver lobules, and in D, the end-stage of 
cirrhosis is visible (Sirius red staining). Photo by Kajsa Villiamsson, Karolinska Institutet.  
 
Figure 5. Diagnostic algorithm of NASH according to the SAF scoring system. From 
Bedossa et al, Hepatology 2014;60:565-575. Published with permission.  
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1.1.2 Prognosis in non-alcoholic fatty liver disease 
The increase in the prevalence of NAFLD (13, 42) together with the astonishing success of 
new direct acting antiviral drugs to cure HCV (43) indicates that NAFLD will likely become 
the major cause of advanced liver disease in the near future. Indeed, in the US NAFLD is 
already the number two cause for need for liver transplantation, and is projected to be number 
one after 2020 (44). 
Patients with NAFLD have an increase in overall as well as cardiovascular and liver-specific 
mortality (15, 45-48), but making an individual prognosis in NAFLD is challenging. Firstly, 
the prevalence of NAFLD is staggering, making the potential numbers needed to screen to 
detect cases with or at risk for advanced liver disease enormous. Secondly, only a 
subpopulation of patients with NAFLD goes on to develop NASH, progressive fibrosis or 
cirrhosis. Thirdly, the rate at which NAFLD patients develop progressive fibrosis is varying, 
with some data to support a rate of 7-14 years for progression of one fibrosis stage (49). Thus, 
the need for tools to be able to identify patients at risk for adverse outcomes is huge.  
There has been considerable debate on if NAFLD is a disease entity in its own right, or if it is 
simply an epiphenomenon of the metabolic syndrome. However, in recent years the current 
paradigm has shifted toward a recognition that patients with NAFLD are at increased risk for 
overall and disease-specific mortality, as well as morbidity (50, 51). Adams et al produced 
the first major study in 2005 of the natural history of NAFLD patients, and showed that 
NAFLD patients had a roughly 30% increased risk for death, and that death in liver disease 
was the third leading cause of death, compared to being the thirteenth most common cause of 
death in the reference population (15). Since then, a number of studies have addressed the 
prognosis and natural history of NAFLD, of which two major studies are Swedish. Ekstedt et 
al performed an elegant study of 129 NAFLD patients, where 71 had undergone two liver 
biopsies during a mean follow-up of 13.8 years, and showed that primarily patients with 
NASH had an increased risk of death. Progressive fibrosis between the two biopsies was 
associated with weight gain and development of diabetes (47). From Stockholm, Söderberg et 
al confirmed this finding in 118 NAFLD patients who were followed for up to 28 years, again 
showing that liver disease was the third most common cause of death (46). Also, patients 
with NAFLD has been shown to have an increased risk for carotid intima plaque formation 
independent of confounders (52), is extremely common in patients with myocardial 
infarction, where a higher degree of steatosis has been linked a more severe cardiac artery 
disease, although that particular study was based on ultrasound only (53). 
1.2 PRIMARY SCLEROSING CHOLANGITIS 
Primary sclerosing cholangitis (PSC) is a rare, chronic and progressive disease of the large 
and medium sized bile ducts (54). PSC is highly linked to presence of inflammatory bowel 
disease, with around 80% of PSC-patients having signs of inflammatory bowel disease, and 
PSC is present in roughly 4% of patients with ulcerative colitis (55). The disease is more 
common in the Nordic countries than the rest of the world, with an estimated prevalence in 
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Sweden of around 16 per 100.000 (56), and occurs more often in men than in women (55). 
For unknown reasons, the bile ducts become inflamed and fibrotic, leading to cholestasis and 
increasing the risk for bacterial infections of the bile tree (cholangitis). PSC leads to cirrhosis 
and liver failure in most, but not all cases. Also, the risk for development of 
cholangiocarcinoma in PSC patients compared to healthy controls is dramatically increased 
by some 161 times (57). Mean time from diagnosis to death or need for liver transplantation 
has been estimated to between 12-18 years (58, 59). There is currently no approved therapy 
for PSC (54), and many patients experience a fear for future complications.  
1.3 CIRRHOSIS  
Cirrhosis is the end stage of all chronic liver diseases. Over time, chronic damage to the liver 
results in activation of stellate cells, which resides in the perisinusoidal space. Stellate cells 
have multiple functions, including production of collagen fibres in response to on-going liver 
damage (60, 61). Collagen fibres are deposed in the extracellular matrix of the liver, and 
accumulation of these results in fibrosis. Fibrosis usually starts to form in the portal tracts of 
the liver and can spread between portal tracts and central veins to form a web-like pattern, or 
cirrhosis. However, if the on-going liver damage is removed, such as if an alcoholic patient 
stops drinking or if a viral hepatitis is cured, fibrosis and even cirrhosis can regress (62). 
There are a number of classification systems to stage the amount of fibrosis in the liver on a 
liver biopsy, but most stage fibrosis on a 0-4 scale where 0 means no fibrosis and 4 means 
cirrhosis (38, 63, 64).  
Progression of fibrosis is usually a silent process, and few patients experience any symptoms 
during the course of the disease, and even early stages of cirrhosis are symptom-free. This is 
called compensated cirrhosis. However, with the development of cirrhosis the liver’s function 
starts to fail. The liver has a multitude of functions, including being essential for energy 
homeostasis, production of glucose, many essential proteins and degradation of toxic 
substances from the blood. When these functions start to fail, symptoms do arise and many 
patients experience fatigue, anorexia, bruises easily and can develop liver decompensation. 
1.3.1 Decompensated cirrhosis 
Classical decompensation is the manifestation of bleeding esophageal varices, ascites, 
jaundice or hepatic encephalopathy, all described below. The pathogenesis of these 
symptoms is complicated, but a common denominator is portal hypertension. Cirrhosis leads 
to a higher resistance in the liver to blood from the vena portae and the hepatic artery. 
Furthermore, the oncotic pressure in the blood is reduced in cirrhosis as the production of 
proteins such as albumin is diminished. This combined effect leads to a rise in the pressure in 
the portal vein, which has a number of consequences, described below. These symptoms are 
serious, and in almost all cases lead to hospitalization.  
The prognosis for patients who develop decompensated cirrhosis is dismal. One way to 
predict mortality is the often-used Child-Pugh scoring system (65), which grades cirrhosis in 
three stages, A, B and C depending on the stage of hepatic encephalopathy, ascites and levels 
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of albumin, PK-INR and bilirubin. Patients with Child-Pugh A have a relatively benign 
prognosis, with a one year survival of 100%, while patients with Child-Pugh B have a 80% 
and patients with Child-Pugh C have a 45% one year survival (65). 
1.3.1.1 Ascites 
Ascites is the formation of fluid in the abdominal cavity. With the increase in portal pressure, 
fluid is extruded into the abdominal cavity, forming a transudate which may build up to 15-20 
litres of ascites in the abdomen. Large amounts of ascites can compress the diaphragm and 
the lungs, leading to dyspnoea. Also, bacteria from the gut can translocate into the ascites and 
cause an infection, named spontaneous bacterial peritonitis, which is the most common 
infection in cirrhotics (66). Ascites can be treated with diuretics and/or repeated 
laparocentesis. 
1.3.1.2 Esophageal varices 
With the increase in portal pressure, blood from the splanchnic vessels, which drains through 
the portal vein, must take alternate routes. The most common shunting pathway is through 
small veins in the esophagus, which then can become dilated and form varicose veins, called 
varices. These varices are usually asymptomatic, but can start to bleed, which can lead to 
exsanguination. Esophageal varices can be treated with non-specific beta-blockers as a 
bleeding prophylaxis, which reduce the portal pressure, or repeated band ligation of the 
varices (67). Bleeding varices are treated with vasoactive drugs that reduce portal pressure in 
combination with antibiotics and band ligation (67).  
1.3.1.3 Hepatic encephalopathy 
Hepatic encephalopathy (HE) is a state of confusion related to cirrhosis. Briefly, toxic 
substances from the gut, in particular ammonia, that are usually detoxified by the liver 
bypasses this though shunting via for example esophageal varices. These substances later 
reach the brain and are thought to lead to astrocyte swelling, causing several neurological 
symptoms (68). More recent research has also found that cerebral blood flow is reduced in 
episodes of HE, possibly by inhibition of cerebral energy metabolism related to increased 
ammonia concentrations (69).  
1.3.1.4 Jaundice 
Jaundice is the yellowing of the skin and eyes, caused by increasing amounts of bilirubin in 
the blood. This symptom is not unique to cirrhosis, as bilirubin can increase due to a number 
of other diseases, such as haemolysis or extrahepatic obstruction of the bile ducts. However, 
in cirrhosis bilirubin is increased, as the liver cannot longer keep up with the degradation of 
bilirubin from degraded erythrocytes. 
1.3.1.5 Hepatorenal syndrome  
Hepatorenal syndrome (HRS) is a severe syndrome which can be seen in patients with 
advanced cirrhosis. It is characterized by a rapid deterioration in kidney function in the 
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absence of kidney-specific diseases, and is associated with a dismal prognosis. Hepatorenal 
syndrome is thought to be an effect of vasoconstriction in the renal arteries secondary to 
splanchnic vasodilation seen in advanced cirrhosis. Treatment with albumin and 
vasoconstrictors is commonly applied, which can improve short-term mortality, and patients 
with HRS should be evaluated for liver transplantation (70, 71).   
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1.4 ALCOHOL CONSUMPTION IN SYNCHRONOUS LIVER DISEASE 
It is well known that alcohol consumption can lead to serious liver damage (72), but this is 
the case only in a subset of drinkers (73, 74). Despite this, the exact pathophysiology behind 
alcohol-induced liver damage is not entirely clear. Some 90-95% of heavy drinkers develop 
hepatic steatosis (74), which is thought to occur due to up-regulation of key transcription 
factors involved in lipid metabolism, such as up-regulation of sterol regulatory element 
response-binding protein 1c (SREBP-1c), leading to reduced beta-oxidation and increased de 
novo lipogenesis (74). Alcohol can also induce down-regulation of the nuclear transcription 
factor peroxisome proliferator-activated receptor (PPAR)-alpha, leading to reduced hepatic 
beta-oxidation (75, 76).  
Alcohol is primarily metabolized in hepatocytes to acetaldehyde by cytosolic alcohol 
dehydrogenase, but also by cytochrome P4502E1 in microsomes and catalase in peroxisomes. 
Acetaldehyde is then metabolized by aldehyde dehydrogenase to acetate that is released into 
the blood and used as energy in muscles and by the brain. The intermediary metabolite in this 
pathway, acetaldehyde, is highly reactive and can lead to formation of reactive oxygen 
species and subsequent mitochondrial damage (77, 78). This is thought to lead to activation 
of hepatic stellate cells, but other pathways such as activation of TLR4 and the innate and 
adaptive immune system is also possible (74).  
The traditional way to counsel patients with a concurrent liver disease has been to advice 
complete abstinence from alcohol consumption. The evidence for this however has been 
scarce. Alcohol consumption in low to moderate amounts has been associated with several 
positive as well as negative endpoints. For instance, persons consuming any amount of 
alcohol had a 25% reduction compared to non-drinkers for cardiovascular mortality in a large 
meta-analysis, with the largest benefit in persons who consumed 1-2 drinks per day (79). 
Another large study found a protective effect in moderate drinkers compared to non-drinkers 
for development of rheumatoid arthritis (80). On the other hand, an increased risk for 
development of a number of malignancies has been reported, for example breast and colon 
cancer (81, 82). It can therefore be argued that an individual risk profile should be obtained in 
each individual, with respect to heredity and other risk factors.  
Regarding alcohol consumption in patients with a concurrent liver disease, most evidence 
points to an increased risk for accelerated liver damage in persons consuming high amounts 
of alcohol. For instance, in persons with hepatitis C who consume more than 210 grams of 
alcohol per week, the risk for cirrhosis is increased by 130% compared to non-drinkers (83), 
and one study found an increase in the risk for fibrosis progression even in persons 
consuming low to moderate amounts of alcohol (84). Furthermore, in hereditary 
hemochromatosis, the risk for cirrhosis is increased approximately nine times by drinking 
more than 60 gram of alcohol per day (85).  
The role of alcohol consumption in fibrosis progression in PSC was prior to this thesis not 
explored. However, one study found a possible increase in risk for development of 
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cholangiocarcinoma in PSC-patients who currently consumed any amount of alcohol 
compared to persons who reported never to have consumed any amount of alcohol (86).  
Regarding NAFLD, this is currently a diagnosis of exclusion, meaning that all other liver 
diseases or causes of fat accumulation into the liver must be excluded. This is particularly 
difficult regarding alcoholic liver disease, since the histological picture of NAFLD and 
alcoholic liver disease is almost identical. Thus, significant alcohol consumption must be 
ruled out before the NAFLD diagnosis can be set, which is usually done through a careful 
patient history coupled with analysis of biomarkers. The limit of alcohol consumption that is 
allowed is different in different countries, but is in Sweden set to 30 grams of alcohol per day 
in men and 20 grams in women. One often cited study found that the risk threshold for 
cirrhosis development is around 30 grams of alcohol per day (87). However, a recent Swedish 
study found that consumption of 32 grams of alcohol per day in men and 16 grams per day in 
women for three months did not cause hepatic steatosis (88).  
Binge drinking, usually defined as drinking more than five units of alcohol per occasion, have 
in one study been associated with an increased risk for fibrosis progression in NAFLD (89). 
More recent data, on the other hand, points to a possibly reduced risk for NAFLD in persons 
consuming any amounts of alcohol compared to persons not drinking alcohol (90). Also, in 
subjects with NAFLD, alcohol consumption in moderate amounts has been associated with a 
reduced risk for NASH as well as fibrosis (91). This is in contrast to a number of larger 
studies indicating a possibly synergistic effect of obesity and alcohol consumption on a 
number of biomarkers for liver damage, such as transaminases. In an analysis of 13 580 
persons included in the third US National Health and Nutrition Examination Survey 
(NHANES), alcohol consumption was associated with higher transaminases only in 
overweight and obese participants, suggesting an interaction (92). The same effect has been 
seen in other large studies (93, 94), but all of these studies has used liver transaminases as the 
outcome variable, contrasting to the much more detailed studies with liver biopsies where a 
protective effect of alcohol was seen (91).  
When studying lifestyle related parameters, such as alcohol consumption, one must always 
take into account the possibility of confounding factors. In regard to alcohol, there are several 
potential confounders, including smoking, physical activity and other dietary factors such as 
consumption of fructose and coffee that could partly explain the association between liver 
damage and alcohol consumption (28, 31), which has either been imperfectly or not at all 
been addressed in previous studies.  
1.5 THE IMPACT OF OVERWEIGHT AND OBESITY ON THE LIVER 
Apart from being associated with NAFLD, overweight and obesity has been implicated as 
risk factors in liver disease in a wider sense. In hepatitis C, the presence of hepatic steatosis 
has been independently associated with a faster progression of liver damage (95), and a high 
body mass index has also been linked to a lack of response to antiviral therapy (96) as well as 
to an increased risk for development of HCC (97). In primary biliary cirrhosis (PBC), the role 
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of overweight and obesity is less explored, but one study found that steatosis and a higher 
BMI was each associated with a higher disease stage (98). Another study found that BMI > 
25 and a NAS over five each were associated with more severe bile duct damage (99). 
In more advanced stages of liver disease, an increased risk of around 83% has been found for 
development of primary liver cancer in obese individuals even after adjustment for alcohol 
consumption and viral hepatitis (100). Also, in patients with cirrhosis an increased risk for 
liver decompensation has been found for obese patients, 43% in obese cirrhotics compared to 
15% in patients with cirrhosis and a BMI of <25, after a median follow-up of 59 months 
(101).  
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2 AIMS 
General aims of this thesis were to increase our knowledge of the role of alcohol in 
synchronous liver disease, and to study the prognosis of NAFLD as well as the association 
between overweight and development of liver disease.   
The specific aims of this thesis was to 
1. To study the impact of lifetime alcohol consumption on the severity of liver disease in 
PSC and NAFLD 
2. To study the prognostic impact of several histological parameters on disease-specific 
mortality in NAFLD 
3. To study the prognostic impact of overweight and obesity on the development of 
severe liver disease after an extended follow-up period 
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3 METHODS AND MATERIALS 
3.1 STUDY PARTICIPANTS (STUDY 1, 2, 3 AND 4) 
In study 1, we examined the role of lifetime alcohol consumption on the severity of 
fibrosis in patients with PSC. All patients with PSC at the Karolinska University 
Hospital are recorded at a local register. We used 141 patients that at the time of the 
study were living in the Stockholm area and attended regular follow-up visits at our 
clinic. In total, 45 patients were excluded from the study due to either not being able to 
give informed consent or missing data regarding exposure or outcome variables, 
leaving 96 patients for the final analysis.  
In study 2, we investigated the role of different histological scoring systems on the risk 
of mortality in NAFLD, the NAS and the fibrosis stage (see paragraphs 3.3.1.1 and 
3.3.1.2). We pooled data from two previously studied cohorts regarding the long-term 
prognosis in NAFLD (46, 47), which used patients with confirmed NAFLD 
investigated at the Karolinska University Hospital or the Linköping University Hospital 
for elevated transaminases between 1980-1993.  
Study 3 examined the role of lifetime alcohol consumption in patients with NAFLD. 
We performed a prospective multi-centre study using the “Svensk Internmedicinsk 
LeverKlubb” (SILK) network. This group includes research-focused clinicians from all 
university hospitals in Sweden. For this study, participants from the Karolinska 
University Hospital (data coordinating centre), Linköping University Hospital, 
Sahlgrenska University Hospital, Akademiska University Hospital (Uppsala) and Skåne 
University Hospital contributed to the study. Between 2011 and 2015, 139 subjects 
underwent a liver biopsy during a liver disease workup, and were diagnosed with 
NAFLD. In total, 19 patients were excluded from the study due to missing data 
regarding exposure or outcome data, leaving 120 patients for the final analysis.  
In study 4, we examined the association between BMI in late adolescence and future 
risk for severe liver disease. We used historical data from men who were enlisted for 
conscription between 1969 and 1970. Conscription was mandatory at this time, and 
only persons with severe handicaps were excluded. We obtained data on 49 321 men, of 
which there were complete data regarding all covariates on 44 248 men.  
3.2 ASSESSMENT OF ALCOHOL CONSUMPTION (STUDY 1, 3 AND 4) 
As part of a standard liver disease workup, the question of past and present alcohol 
consumption is always addressed. However, this can be difficult to examine in detail 
due to a number of factors. Firstly, the patient might not want to disclose his or her true 
alcohol habits, since this is perceived as private and high alcohol consumption can be 
stigmatizing. Secondly, recall bias regarding past alcohol consumption might be 
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present. There are a number of methods available to try to quantify an individual 
patient’s past and present alcohol consumption, including questionnaires, techniques in 
taking patient history as well as biomarkers. Some of these take lifetime consumption 
of alcohol into account, but some do not. Only looking at current alcohol consumption 
infers the risk of misclassifying a patient who has had past overconsumption of alcohol, 
but has recently stopped drinking, as a non-drinker.  
In study one and three, we used detailed questionnaires regarding current and lifetime 
alcohol consumption, as well as and specific biomarkers. In study four, data was 
gathered from a register of men who were enlisted for conscription. Data on alcohol 
consumption came from questionnaires describing alcohol consumption at that time, 
and was categorized as 0 grams per week, 1-100 grams per week, 101-250 grams per 
week or more than 250 grams per week.  
3.2.1 Lifetime drinking history questionnaire  
The lifetime drinking history (LDH) is a very detailed questionnaire regarding the 
current and lifetime drinking habits of an individual patient (102). The LDH has been 
validated and has high test-retest correlation (103, 104). It allows for the calculation of 
the total number of units of alcohol during a person’s lifetime, with the possibility of 
calculating changes in drinking habits during life. It also allows measurement of total 
number of binge drinking episodes, defined as drinking five or more units of alcohol at 
one occasion. One unit of alcohol is equivalent to twelve grams of alcohol. In study one 
and three, we used the LDH to assess current and lifetime alcohol intake. Patients were 
thoroughly informed about the questionnaire and later filled it out at home. When data 
were missing, the patient was contacted by telephone and information was 
supplemented through a telephone interview.  
Alcohol consumption was calculated as total units of alcohol intake during a subject’s 
lifetime, and was then divided into units per week. Number of binge-drinking episodes 
was likewise calculated as per drinking week. Drinks consumed during the last week 
before filling in the questionnaire was separately recorded.  
3.2.2 Biomarkers of alcohol consumption 
A number of biomarkers are available to identify excess alcohol consumption. 
However, most biomarkers have low sensitivity and / or specificity and are of minor use 
to clinicians trying to distinguish alcohol-related liver damage from e.g. NAFLD. 
Analysis of transaminases (ALT, AST) is a common first-line step in identifying liver 
damage per se, but carries the risk of misclassification since primarily AST can be 
increased in a number of other scenarios, most commonly muscular damage. Other 
markers of recent alcohol consumption includes gamma-glutamyltransferase (GGT) and 
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mean corpuscular volume (MCV), which are both non-specific and can be increased in 
other diseases than alcohol-related liver disease (105).  
More specific markers of recent alcohol consumption include carbohydrate-deficient 
transferrin (CDT) and phosphatidyl ethanol (PEth). The CDT test is often used 
internationally, while PEth is more common in Sweden. An increase in CDT is evident 
first after consumption of 50-80 grams of alcohol per day during at least one week 
(106), which is much higher than the normally recommended safe intake of 20-30 
grams per day (73), meaning that subjects consuming between 30-50 grams per day will 
not be identified by the CDT test. Phosphatidyl ethanol is relatively new biomarker, of 
which the 16:0/18:0 variant has been identified as the most sensitive biomarker for 
alcohol consumption during the preceding 2-3 weeks (107, 108). The correlation 
between PEth and alcohol intake is roughly linear, and there has been no reports of 
false-positive increases in PEth in subjects who abstain from alcohol.   
In study 1 and 3, we used CDT and PEth as markers of recent alcohol consumption in 
the respective cohorts.  
3.3 ASSESSMENT OF LIVER DAMAGE 
As most liver diseases are asymptomatic at first, assessment of the grade of liver 
damage can be challenging. Non-invasive biomarkers, such as liver transaminases are 
usually a first-line test to identify subjects with an on-going liver injury. However, these 
biomarkers are not perfect, and for instance in NAFLD, the entire spectrum of liver 
disease from benign liver histology to cirrhosis can be seen in NAFLD patients with 
normal transaminases (109).  
As discussed above, with manifest cirrhosis the function of the liver starts to fail, and 
this can be seen in laboratory parameters such as albumin, bilirubin and PK-INR. 
However, this indicates already manifest severe liver disease, and there is a need to be 
able to pick up these cases earlier in the disease continuum, when the disease in 
question is potentially treatable and before cirrhosis appear.  
In study two and three, all subjects were examined with a liver biopsy, and in study one 
all subjects were examined using transient elastography (described below). In study two 
and four, outcome data were obtained from national, population-based registers.  
3.3.1 Liver biopsy (study 2 and 3) 
The gold standard for diagnosis of a number of liver diseases is to perform a liver 
biopsy. Liver biopsies have been performed since the 1920:s, and allow a pathologist to 
evaluate the biopsy for a number of different characteristics, including steatosis, 
fibrosis, inflammation and bile duct damage (110). However, being an invasive 
procedure liver biopsy is associated with a number of risks. The mortality associated 
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with liver biopsy has been estimated to 1/1000 – 1/10000, and patients with cirrhosis 
are at an increased risk for mortality (110). 
In study two, 149 biopsies from the 229 patients with NAFLD were re-examined by a 
single expert liver pathologist (R.H.), blinded to patient characteristics and scored for 
the NAS and for fibrosis scores. Six biopsies were of poor quality and were not used for 
analysis. Seventy-four liver biopsies were not available for re-examination, but had 
previously been reassessed by an experienced liver pathologist as part of one of the 
prior follow-up studies (47). There was a low reproducibility (κ = 0.062) of 
hepatocellular ballooning and lobular inflammation between the two pathologists. 
Therefore, these 74 patients were excluded from the analyses of NAS. However, they 
were still included in the analyses of fibrosis stage, as the agreement on fibrosis stage 
between the two pathologists was substantially higher (κ = 0.73) 
In study three, the same expert liver pathologist examined all biopsies centrally and 
scored these for NAS and fibrosis scores.  
3.3.1.1 NAFLD activity score (NAS) 
As described in the introduction, the NAS is a semi-quantitative scoring system of 
biopsies from NAFLD patients. The score incorporates fat, ballooning and lobular 
inflammation. Fat is scored on a scale of 0-3, where 0 indicate that between 0-5% of the 
surface area of the biopsy is steatotic, 1 indicate that 5-33% is steatotic, 2 indicate that 
33-66% is steatotic and 3 indicate that > 66% is steatotic. Ballooning is scored on a 0-2 
scale, where 0 indicate no ballooning, 1 indicate few ballooned cells and 2 indicate 
many ballooned cells or prominent ballooning. Lobular inflammation is scored on a 0-3 
scale, where 0 indicate no lobular inflammation, 1 indicate <2 foci per 200 x field, 2 
indicate 2-4 foci per 200 x field and 3 indicate more than 4 foci per 200 x field. This 
yields a total score of 0-8 (38).  
3.3.1.2 Fibrosis score 
Fibrosis was scored according to the Kleiner fibrosis score (38) on a 0-4 scale, where 0 
indicate no fibrosis, 1 indicates periportal or perisinusoidal fibrosis, 2 indicate 
perisinusoidal and periportal or portal fibrosis, 3 indicate bridging fibrosis and 4 
indicate cirrhosis.  
3.3.2 Transient elastography (study 1) 
In study one, we did not consider it ethical to perform a liver biopsy in roughly 100 
PSC patients with known disease and where a liver biopsy should add very little, if 
anything, to the individual prognosis. Instead, we performed transient elastography on 
all participants.  
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Transient elastography (TE) is relatively new ultrasound-based technique to estimate 
the stiffness of the liver, and uses both ultrasound and low-frequency elastic waves 
formed by an air compressor probe, and whose propagation velocity is related to liver 
elasticity (111). This allows the estimation of liver fibrosis in a non-invasive manner. 
Results are expressed as kilopascals (kPa). The TE technique is most validated in 
patients with hepatitis C (112), but had at the time of study one also been tested in 
patients with PSC, where a cut-off of 17.3 kPa for detection of cirrhosis was found 
(113).  
We divided the population into two subgroups: patients with significant and non-
significant fibrosis. Significant fibrosis was defined as either elastography values ≥ 17.3 
kPa, based on the available evidence (113), or a clinical diagnosis of cirrhosis 
diagnosed with histology or typical radiological and biochemical findings of cirrhosis 
(such as irregular hepatic parenchyma, splenomegaly, oesophageal varices, presence of 
intraabdominal collaterals) or previous manifestation of liver decompensation. In nine 
patients elastography failed, most often due to overweight or obesity. In six of these, 
presence of significant fibrosis was evident from clinical data and they were included 
into the “significant fibrosis” group. The three patients with no available information on 
fibrosis from either elastography or clinical data were excluded.  
3.3.3 Swedish population-based registers (study 2 and 4) 
The Nordic countries including Sweden are unique in regard to having extensive, 
detailed and population-based registers of its populations. This allows for high-quality 
epidemiological research with very low loss to follow-up. There are a number of 
registers, of which the causes of death register and the patient registers were used for 
study two and four. All of these registers are based upon the unique personal 
identification number. 
3.3.3.1 The personal identification number 
All Swedish citizens are given a unique, ten-digit personal identification number (PIN) 
after birth or immigration. This allows for linkage to and between registers (114).  
3.3.3.2 Causes of death register 
The Causes of Death Register (CDR) contains data from 1961 regarding the causes of 
death of all Swedish citizens, including if the person died abroad. It is mandatory for 
the responsible physician to report the underlying cause of death (e.g. stroke) and any 
disease that could have contributed to the death of the individual (e.g. atrial fibrillation).  
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3.3.3.3 Patient register 
The National Patient Register (NPR) was established in 1964, and includes information 
on dates of hospital admissions, discharges, and diagnoses classified according to 
International Classification of Diseases (ICD) codes, 7-10. The register also includes 
information on hospital-based outpatient visits since 2001. The coverage of the register 
is approximately 99% of all somatic discharge diagnoses, and the validity of hospital 
discharge diagnoses is between 85-95% depending on diagnosis (115). 
3.3.3.4 Total population register 
The total population register contains data from the Swedish tax agency, and contains 
data on PIN, sex, age and living location as well as on emigration from Sweden. For 
study two, we used this register to create a matched control population. For each case 
with NAFLD, ten controls were selected and matched for sex, age and living location at 
the time of the initial liver biopsy.  
3.3.4 Outcome variables  
For study two, we examined causes of death in the cases that had died, with data drawn 
from the CDR. Cases with NAFLD and matched controls were cross-checked against 
the CDR, and disease-specific causes of death according to the ICD 8, 9 or 10 versions 
were obtained.  
For study four, we used diagnoses of liver cirrhosis, decompensated liver disease 
(ascites, esophageal varices [bleeding or not bleeding], hepatorenal syndrome or hepatic 
encephalopathy), hepatocellular carcinoma or liver failure from the NPR, or death from 
any of the above in the CDR as our primary end point variable severe liver disease. 
This endpoint was chosen to identify as many true cases as possible, as all of these 
diagnoses usually lead to hospitalization and thus entry into the NPR, or death and thus 
entry in the CDR.  
3.4 STATISTICS 
3.4.1 Study 1 
Continuous variables were analysed using the Mann-Whitney U-test or the Wilcoxon 
Signed Rank Test where appropriate. For comparison of categorical data the χ2 analysis 
was used or, in the case of small expected frequencies, the Fisher exact test. For 
correlation tests of linear data, the Pearson r test was used. We controlled the results for 
duration of disease using co-variance analysis of variance. Statistical analyses were 
done using the Statistica® 9.1 software (StatSoft Inc., Tulsa OK) and SAS 9.2 software 
(SAS Institute Inc., Cary NC). 
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3.4.2 Study 2 
Continuous variables are presented as mean (standard deviation), and categorical 
variables are presented as number (percentage). Histopathological agreement was 
analysed by the kappa (κ) coefficient. Analyses of mortality risks were done with the 
proportional hazard model (Cox regression), stratified on matching number. The model 
was tested for proportionality with Schoenfeld residuals. Survival curves were made 
according to the Kaplan-Meier method. All statistical analyses were performed with 
Stata v. 12.1 (StataCorp, College Station, Texas, US). P < 0.05 was considered 
statistically significant. 
3.4.3 Study 3 
Differences between continuous variables were analysed using the Mann-Whitney U-
test, and between categorical variables using Fisher’s exact test. We applied an ordinal 
logistic regression model to estimate the effect of alcohol consumption on the stage of 
fibrosis after checking for the assumption of proportionality, and a logistic regression 
model to estimate the effect of alcohol consumption on the presence of NASH. In a 
separate model, we divided the cohort into two groups, stratified on the median weekly 
alcohol consumption. We used a stepwise forward approach to identify any potential 
parameter associated with the studied outcome, using a p-value of ≤ 0.1 as significant 
and constructed one crude univariate model per parameter and one multivariate model 
including all significant parameters. The multivariate models included lifetime alcohol 
consumption per drinking week as the primary independent variable, and the full model 
was adjusted for age at biopsy, diabetes mellitus type 2, arterial hypertension, BMI and 
smoking status, dichotomized as ever or never. Data are presented as odds ratios (OR) 
with 95% confidence intervals (CI), with a significance level of 0.05. All analyses were 
performed using STATA version 12.1 (StataCorp, College Station, Texas, US).    
3.4.4 Study 4 
After exclusion of missing data, a final sample of 44 248 men was available. The 
association with BMI as a continuous variable was calculated using Mann-Whitney 
rank sum test for dichotomous variables and Spearman rank correlation for categorical 
and continuous variables. A multivariate Cox regression model was used to assess the 
effect of BMI on the outcome of severe liver disease. We tested BMI both as a 
continuous and as a categorical variable. We used a stepwise forward approach to 
identify any potential parameter associated with the primary outcome variable of severe 
liver disease, using a p-value of ≤ 0.1 as significant. The final models with BMI as a 
continuous variable and BMI as a categorical variable were consequently adjusted for 
alcohol consumption, use of narcotics, smoking, cognitive ability and high blood 
pressure at conscription. Estimates of the final models are presented as Hazard ratios 
(HR). The men were followed until the first registered diagnosis of severe liver disease, 
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death of any cause, emigration or the end of the follow-up period. After emigration the 
men were considered lost to follow-up but contributed with the time until emigration to 
the analysis. All analyses were performed in STATA 13.0 (StataCorp, College Station, 
Texas, USA) and a two-sided alpha value of 0.05 was used to test for statistical 
significance. 
 
3.5 ETHICAL CONSIDERATIONS 
The local ethical committee at Karolinska Institutet approved all studies in this thesis. 
For study one and three, individual written and oral informed consent was obtained in 
all cases.  
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4 RESULTS 
4.1 STUDY 1 
We identified 96 patients with PSC and complete data on exposure and outcome. There 
were 66% men, mean age was 47 ± 13 years (range: 22-75 years) and 73 patients (76%) 
were diagnosed with concomitant inflammatory bowel disease (IBD). Mean 
elastography value was 11.1 ± 8.2 kPa (range: 2.8-48 kPa). Seven patients (7.3%) had 
been diagnosed with PSC before they first started drinking alcohol. There were no cases 
of patients with Child-Pugh score of 10 (i.e., class C) or higher. 
Mean lifetime alcohol intake was 3882 units (median: 2275 units, range: 0-20 270 
units), giving a mean weekly consumption of 2.6 units per week. Only nine percent 
(9/96) drank equal to or more than one unit per day, and only one person had a mean 
consumption of more than two units per day. We classified 26 patients as having 
significant fibrosis, and 70 patients as not having significant fibrosis.  
There were no significant differences in mean units of alcohol consumed per year 
between patients with significant and non-significant fibrosis. There was no correlation 
between yearly alcohol intake and elastography values. A scatterplot of mean drinks per 
year versus elastography values is presented in figure 6. To further evaluate if the 
drinking habits changed after PSC diagnosis, the LDH data were compared before and 
after PSC diagnosis. Among patients with non-significant fibrosis, we found an increase 
in total alcohol consumption after PSC diagnosis (111 units per year vs. 151 units per 
year, P = 0.07) whereas a decrease in total alcohol consumption after PSC diagnosis 
(103 units per year vs. 88 units per year, P = 0.59) was found in the significant fibrosis 
group. Binge-drinking before and after PSC diagnosis was 14.9 binges per year vs. 9.6 
binges per year (P = 0.24) in the non-significant fibrosis group and 4.3 binges per year 
vs. 3.6 binges per year (P = 0.5) in the significant fibrosis group. The significant 
fibrosis group had lower CDT values (0.88% vs. 1.06%, P = 0.02) and lower PEth 
values (0.1 vs. 0.33, P = 0.0016) than the non-significant fibrosis group.  
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Figure 6. Scatterplot of drinks per year versus elastography value, expressed in 
kPa, from study 1. World Journal of Gastroenterology 2012. Published with permission. 
4.2 STUDY 2  
The original histology reports were available on all 229 patients from the two previous 
studies. Of the 149 patients with complete histological data, 76 patients (49%) had NAS 
0-4 and fibrosis stage 0-2, 57 patients (37%) had NAS 5-8 and fibrosis stage 0-2, eight 
patients (5%) had NAS 0-4 and fibrosis stage 3-4, and finally eight patients (5%) had 
NAS 5-8 and fibrosis stage 3-4. Of the 74 patients in whom histology were missing for 
re-evaluation, 65 (86%) had fibrosis stage 0-2 and 11 (14%) had fibrosis stage 3-4.  
The cohort was followed for a mean of 26.4 years (±5.6, range 6-33), or 5.400 person 
years. During follow-up, 96 patients and 786 individuals from the reference population 
died. In six patients and 40 reference individuals no cause of death was provided from 
the Registry of Causes of Death, which is either due to death in recent time or missing 
data entry from the reporting clinician. These patients were included in the analysis of 
overall mortality, but left out in the analysis of disease-specific mortality. Four patients 
emigrated during the study period and were lost to follow-up. These patients still 
contributed with 31 years of follow-up time to the analysis. Overall mortality in the 
entire cohort was significantly increased, with a hazard ratio (HR) of 1.29 (95% 
confidence interval [CI] 1.04-1.59, P = 0.020).  
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In the subgroup of patients with NAS 0-4 and fibrosis stage 0-2, overall mortality was 
not increased compared to the reference population (HR 1.13, 95% CI 0.79-1.60, 
P = 0.51). There were no cases of HCC in this group. Death from events related to 
cirrhosis was significantly increased (HR 4.86, 95% CI 1.08-22.0, P = 0.04). This was 
due to death of two patients with cirrhosis, with fibrosis stage 2 at baseline. Neither 
death from cardiovascular disease, non-gastrointestinal malignancy, or other diseases 
was significantly increased compared to the reference population.  
In the subgroup of patients with NAS 5-8 and fibrosis 0-2, overall mortality was not 
increased (HR 1.41, 95% CI 0.97-2.06, P = 0.07). Death from HCC was significantly 
increased (HR 15.67, 95% CI 4.1-59.86, P  < 0.001). Mortality from cardiovascular 
disease (CVD) was not different from that of the reference population (HR 1.38, 95% 
CI 0.72-2.65, P = 0.34). There was also an increased risk of death from respiratory 
diseases, e.g., chronic obstructive pulmonary disease or asthma (HR 3.95, 95% CI 1.2-
13.0, P = 0.024).  
Apart from three deaths from HCC, there were no cases of death from events linked to 
cirrhosis in this group. All patients with HCC in this group had developed cirrhosis 
during follow-up, and the fibrosis stages at baseline were 0, 2, and 2, respectively, in 
these patients. Mortality from other diseases was not different compared to the 
reference population (data not shown).  
There were no significant differences regarding any cause of death between the groups 
NAS 0-4 / fibrosis stage 3-4 and NAS 5-8 / fibrosis stage 3-4. Therefore, the data in this 
group were pooled and analysed together. The overall mortality in this group (NAS 0-8, 
fibrosis stage 3-4) was significantly increased (HR 3.3, 95% CI 2.27-4.76, P  < 0.001).  
A table of hazard ratios for disease-specific causes of death in the respective subgroups 
is presented in table 2, and Kaplan-Meier curves for the entire cohort and the respective 
subgroups is presented in figure 7.  
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Cause of Death Entire 
Cohort 
(n = 229) 
P NAS 0-4, 
F0-2 
(n = 76) 
P NAS 5-8, 
F0-2 
(n = 57) 
P NAS 0-8, 
F3-4 
(n = 16) 
P 
Overall mortality 1.29 
(1.04-
1.59) 
0.020 1.13 
(0.79-
1.60) 
0.511 1.41 
(0.97-
2.06) 
0.072 3.28 
(2.27-
4.76) 
<0.001 
Cardiovascular 
disease 
1.55 
(1.11-
2.15) 
0.01 1.19 
(0.65-
2.20) 
0.557 1.38 
(0.72-
2.65) 
0.335 4.36 
(2.29-
8.29) 
<0.001 
Hepatocellular 
carcinoma 
6.55 
(2.14-
20.0) 
0.001 No 
outcome 
— 15.7 
(4.1-
59.9) 
<0.001 16.9 
(1.95-
146) 
0.01 
Cirrhosis 3.2 
(1.05-
9.81) 
0.041 4.86 
(1.08-
22.0) 
0.04 No 
outcome 
— 10.8 
(1.38-
83.9) 
0.023 
Gastrointest- 
inal malignancy 
0.60 
(0.22-
1.64) 
0.322 1.26 
(0.60-
2.65) 
0.546 0.54 
(0.075-
3.96) 
0.548 No 
outcome 
— 
Nongastro- 
intestinal 
malignancy 
1.18 
(0.70-
1.98) 
0.545 1.24 
(0.55-
2.76) 
0.602 0.85 
(0.27-
2.65) 
0.778 No 
outcome 
— 
Infectious disease 2.71 
(1.02-
7.26) 
0.046 3.12 
(0.72-
13.5) 
0.129 2.22 
(0.31-
16.4) 
0.435 13.0 
(3.13-
54.5) 
<0.001 
Respiratory disease 1.01 
(0.31-
3.32) 
0.979 No 
outcome 
— 3.95 
(1.22-
13.0) 
0.024 No 
outcome 
— 
Table 2. Hazard ratios for disease-specific causes of death in the respective 
histopathological subgroups in study 2. 
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Figure 7. Kaplan-Meier curves for the entire cohort and the respective subgroups 
in study 2. Hepatology 2015. Published with permission. 
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4.3 STUDY 3 
Between 2011 and 2015, 139 subjects were identified and gave informed consent. Of 
these, 7 had < 5% of fat in the biopsy and were excluded as were another eleven 
subjects who did not return the questionnaires despite reminder. In one case, the biopsy 
was unavailable for analysis. This left 120 patients for analysis. Furthermore, 13 
subjects had a PEth value of ≥ 0.3 μmol/L (median 0.52, range 0.31-1.05), indicating 
more pronounced recent alcohol consumption than reported at the visit or in the 
questionnaires; these 13 subjects were evaluated separately and not included in the 
primary statistical models.  
4.3.1 Alcohol consumption 
Lifetime consumption of alcohol in the cohort was reported at a median of 1.1 units per 
week (range 0-13.2). Binge-drinking occurred at a median of 1.2 times per year (range 
0-45). There were no statistically significant differences between persons who 
consumed less versus more than the median weekly consumption of alcohol (1.1 units / 
week) in regard to any of the studied potential confounders.   
4.3.2 Impact of alcohol on liver histology 
Up to a maximum of 13 reported drinks per week, each additional unit in alcohol 
consumption was associated with decreasing odds ratios (OR) for having a higher 
fibrosis stage, both in the univariate model (OR, 0.86; 95% confidence interval [CI], 
0.77-0.97; p=0.016) and in the multivariate model (adjusted [a] OR, 0.86; 95% CI, 
0.76-0.97; p=0.017). Association between tested variables, including alcohol 
measurements, are presented in table 3. 
When dividing the cohort in two groups, more or less than the median weekly lifetime 
alcohol consumption of 1.1 units/week, the 50 subjects who consumed more had lower 
odds ratios for a higher fibrosis stage than the 57 subjects who consumed less than 1.1 
units/week, both in the univariate (OR 0.37; 95% CI, 0.18-0.75; p=0.006) and in the 
multivariate (aOR 0.38; 95% CI 0.18-0.80; p=0.01) analyses. Binge drinking was not 
associated with fibrosis stage (OR 0.97; 95% CI 0.93-1.01; p=0.11). When dividing 
binge drinking into quartiles (0, 0.1-0.9, 0.9-4.0, 4.0-45), the highest quartile (>4 
episodes per year, N=27) did not have a higher fibrosis stage than the three lower 
quartiles (1.5 vs. 1.8, p=0.38). 
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Variable OR, 95% CI P-value aOR, 95% CI P-value 
Units of alcohol 
per week
1
 
0.86, 0.77-0.97 0.016 0.86, 0.76-0.97 0.017 
Diabetes mellitus 
type 2 
2.91, 1.40-6.05 0.004 2.63, 1.13-6.14 0.025 
Hypertension 2.21, 1.10-4.47 0.027 1.35, 0.55-3.30 0.51 
BMI
1
 1.06, 0.98-1.14 0.15 1.04, 0.97-1.13 0.28 
Smoking, ever 1.46, 1.01-2.09 0.042 1.26, 0.84-1.89 0.27 
Age at biopsy
1
 1.02, 1.00-1.04 0.042 1.00, 0.97-1.03 0.84 
Drinks per 
drinking day
1
 
0.95, 0.82-1.10 0.46 - - 
Number of binges 
per year
1
 
0.97, 0.93-1.01 0.11 - - 
AUDIT score
1
 1.01, 0.88-1.17 0.86 - - 
Coffee 
consumption
2 
Soft drink 
consumption
2
 
1.01, 0.98-1.03 
 
1.00, 0.96-1.03 
0.67 
 
0.81 
- 
 
- 
- 
 
- 
Physical activity
3
 0.87, 0.64-1.20 0.40 - - 
Table 3. Crude and adjusted odds ratios for increasing fibrosis stage in study 3. 
1
 
For each unit increase. 
2 
For each unit increase per week.
 3
For each step increase on a 6-digit scale. 
Abbreviations: OR, odds ratio. CI, confidence interval. aOR, adjusted odds ratio. BMI, body mass index. 
AUDIT, alcohol use disorders identification test. 
 
The thirteen subjects with PEth values ≥ 0.3 μmol/L had almost three-times increased 
odds ratios for having higher more advanced stages of fibrosis than subjects with PEth 
< 0.3 μmol/L, both in the univariate (OR 2.76; 95% CI 1.06-7.21; p=0.038) and in the 
multivariate models (aOR 2.77; 95% CI 1.01-7.59; p=0.047). Subjects with 
intermediate PEth values (0.05-0.3 μmol/L) did not have an increased risk for a higher 
fibrosis stage, compared to subjects with PEth <0.05 μmol/L (OR 0.80; 95% CI 0.30-
2.10; p=0.65). 
Crude odds ratios for associations of the study variables with the presence of NASH, as 
defined by the FLIP algorithm, are presented in Table 4. No association for any studied 
lifetime alcohol consumption parameter with a NASH diagnosis was found. Only 
smoking was identified as a potential confounder on NASH diagnosis in the univariate 
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analysis (OR 0.66; 95% CI 0.43-1.00; p=0.05) and a trend was noted for BMI (OR 1.08 
for each unit increase in BMI, 95% CI 0.99-1.18; p=0.09). Soft drink or coffee 
consumption did not differ between subjects with and without NASH (mean 3.8 vs. 3.6 
per week, p=0.67; and mean 13.4 vs. 15.5 cups per week, p=0.82, respectively).  
Subjects with PEth ≥ 0.3 μmol/L had overall higher NAS (5.6 vs. 4.2, p=0.004) and a 
substantially increased risk of NAS ≥ 5, both in the univariate (OR 7.58; 95% CI 1.60-
35.87 p=0.01) and in the multivariate analysis (aOR 17.09; 95% CI 2.03-143.56, 
p=0.009).  
4.3.3 Blood parameters 
Subjects who consumed more than the median amount of 1.1 units of alcohol per week 
had lower values of inflammatory markers, including TNF-alpha (8.6 vs. 10.5 ng/L, 
p=0.05) and highly sensitive CRP (2.4 vs. 5.3 mg/L, p=0.004). There were no 
significant differences in lipid profiles or transaminases (data not shown).  
 
 
Variable OR, 95% CI P-value 
Units of alcohol per week
1
 0.98, 0.86-1.11 0.71 
Diabetes mellitus type 2 1.01, 0.46-2.22 0.99 
Hypertension 1.06, 0.49-2.32 0.88 
BMI
1
 1.08, 0.99-1.18 0.09 
Smoking, ever 0.66, 0.43-1.00 0.05 
Age at biopsy
1
 1.01, 0.98-1.04 0.48 
Drinks per drinking day
1
 0.99, 0.83-1.17 0.9 
Number of binges per year
1 
PEth ≥ 0.3 μmol/L 
0.99, 0.95-1.04 
3.55, 0.75-16.84 
0.79 
0.11 
 
Table 4. Crude odds ratios in association with NASH defined as per the FLIP 
algorithm in study 3. 1For each step increase. Abbreviations: OR, odds ratio. CI, confidence 
interval. BMI, body mass index. PEth, phosphatidyl ethanol. 
 
  31 
4.4 STUDY 4 
Out of the 44 248 men included in the univariate analyses, 2 935 (6.6%) were 
overweight with a BMI equal to or greater than 25 (mean BMI: 21.0, range: 12.9-44.6). 
Of these, 352 (0.8%) were obese with a BMI equal to or greater than 30. Baseline data 
per BMI category are presented in Table 5. All the covariates were significantly 
associated with level of BMI although the sizes of the difference were rather small. For 
example, level of alcohol consumption did not differ much between BMI categories 
(Table 5). Smoking was common at conscription with 58.4% reporting being a smoker. 
Although the proportion of non-smokers was similar across the BMI-categories, the 
proportion of men smoking more than 10 cigarettes a day increased with increasing 
BMI. Overall, the categories below a BMI of 25 displayed the lowest rate of poor health 
behaviours and highest ranks of health markers, except for use of narcotics that 
decreased with an increasing BMI.  
The association for development of severe liver disease per covariate is presented as 
crude hazard ratios in Table 6. Alcohol consumption was associated to development of 
severe liver disease later in life in a dose-dependent fashion. Compared to drinking 1-
100 grams of alcohol per week, the relative risk increased among those consuming 101-
250 grams of alcohol per week (HR 1.82, 95%CI 1.48-2.30, p<0.001) or more than 250 
grams per week (HR 5.38, 95%CI 4.06-7.13, p<0.001). Similarly, smoking was 
associated with development of severe liver disease later in life comparing to non-
smokers in a dose-dependent fashion from 6-10 cigarettes per day (HR 1.43, 95%CI 
1.09-1.89, p<0.001) to more than 20 cigarettes per day (HR 4.74, 95%CI 3.38-6.64, 
p<0.001). Likewise, use of narcotics, high blood pressure, poor self-rated health, low 
cardiovascular fitness and low cognitive ability were associated with development of 
severe liver disease later in life.  
The men were followed for a period of in mean 37.8 years (SD ± 5.0, range 0.1-39) or 1 
674 527 person-years. During this time, 3 101 men died and 424 men, 0.96%, 
emigrated and were considered lost to follow-up. A total of 393 men were diagnosed 
with severe liver disease. Of these, 174 cases were first diagnosed with decompensated 
liver disease and 165 cases were first diagnosed with liver failure or cirrhosis as first 
diagnosis. In addition, 54 men died with liver disease reported as main or underlying 
cause of death. A total of 213 out of the 393 cases of severe liver disease died during 
the follow-up period. Mean time to the first diagnosis of severe liver disease was 24.7 
years (SD ± 11.4, range 3-39).  
4.4.1 Body mass index as a predictor of severe liver disease 
BMI as a continuous variable was significantly associated with an increased risk of 
severe liver disease, both in the univariate (HR 1.06 per each unit increase in BMI, 
95%CI 1.02-1.09, p=0.002) and the multivariate models (HR 1.05 per each unit 
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increase in BMI, 95%CI 1.01-1.09, p=0.008) (Table 7). When analysing BMI as a 
categorical variable, BMI 25-30 was associated with an increased risk for severe liver 
disease in the univariate model (HR 1.72, 95%CI 1.21-2.45, p=0.002) as well as in the 
multivariate model (HR 1.64, 95%CI 1.16-2.32, p=0.006) compared to participants with 
BMI 18.5-22.5 (Table 7). A Kaplan-Meier curve for the development of severe liver 
disease, stratified on overweight status is presented in figure 8. 
 
 
BMI 
N 
<18.5 
6119 
18.5-22.5 
28450 
22.5-25.0 
6744 
25.0-30 
2583 
≥30 
352 
p-value 
Alcohol      <.001 
0 g/week (%) 5.5 6.9 6.5 6.8 7.9  
1-100g/week (%) 70.7 71.5 69.1 69.9 67.9  
100-250 g/week (%) 20.3 18.8 20.3 19.3 19.9  
>250 g/week (%) 3.5 2.8 4.1 4.1 4.3  
Smoking      <.001 
Non-smoking (%) 41.5 36.5 45.5 43.1 40.1  
1-5 cig/day (%) 11.6 11.5 10.4 8.4 8.2  
6-10 cig/day (%) 21.1 24.3 17.4 17.8 15.6  
11-20 cig/day (%) 22.6 24.3 22.9 25.7 31.3  
>20 cig/day (%) 3.3 3.4 3.9 5.1 4.8  
Use of narcotics (%) 13.7 12.0 10.0 7.1 6.8 <.001 
High BP (%) 6.6 8.0 10.9 18.4 38.6 <.001 
Cognitive ability (mean) 5.4 5.5 5.3 5.0 4.8 <.001 
Self-rated health (mean) 1.9 1.8 1.8 1.9 1.9 <.001 
Cardiovascular fitness (mean) 4.7 6.1 6.9 6.7 6.1 <.001 
Table 5. Mean values per covariate, stratified on BMI-category in study 4. Associations 
between variables and BMI have been tested using Mann-Whitney rank sum test for dichotomous 
variables and Spearman rank correlation for ordinal and continuous variables. Abbreviations: BMI: Body 
Mass Index. BP: Blood Pressure. Cig: Cigarettes. 
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Variable HR (95% CI) p-value 
Alcohol   
0 g/week .71 (.41-1.25) .24 
1-100 g/week Ref  
100-250 g/week 1.85 (1.47-2.33) <.001 
>250 g/week 5.37 (3.99-7.22) <.001 
Smoking   
Non-smoking Ref  
1-5 cig/day 1.15 (.77-1.72) .50 
6-10 cig/day 1.53 (1.13-2.06) .005 
11-20 cig/day 2.61 (2.02-3.37) <.001 
>20 cig/day 5.17 (3.61-7.41) <.001 
Use of narcotics 3.17 (2.55-3.95) <.001 
High BP 1.29 (0.95-1.77) .10 
Cognitive ability
1
 .88 (.85-.93) <.001 
Self-rated health
2
 1.24 (1.12-1.37) <.001 
Cardiovascular fitness
1
 .90 (.86-.95) <.001 
Table 6. Crude HRs for development of severe liver disease per covariate in study 4. 
1
Hazard ratios for each step increase on the 9-point scales. 
2
Hazard ratios for each step increase on the 5-
point scale. Abbreviations: SD: Standard Deviation. HR: Hazard Ratio. CI: Confidence Interval. BP: 
Blood Pressure. Cig: Cigarettes. 
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BMI Crude p-value Adjusted
1
 p-value 
Continuous
2
 1.06 (1.02-1.09)  0.002 1.05 (1.01-1.09) 0.008 
Categorical     
<18.5 1.12 (0.84-1.50) 0.45 1.11 (0.83-1.49) 0.47 
18.5 – 22.5  1.0 Ref  1.0 Ref 
22.5 – 25 1.15 (0.87-1.51) 0.34 1.17 (0.89-1.55) 0.26 
25-30 1.72 (1.21-2.45) 0.002 1.64 (1.16-2.32) 0.006 
> 30 1.82 (0.75-4.40) 0.19 1.59 (0.64-3.95) 0.31 
Table 7. Crude and adjusted hazard ratios with 95% confidence intervals for 
development of severe liver disease depending on BMI at time of conscription in study 4. 
1
Adjusted for alcohol consumption, use of narcotics, smoking, high blood pressure and cognitive ability at 
conscription. 
2
HR corresponds to increased risk for severe liver disease per each unit increase in BMI. 
Abbreviation: BMI: Body Mass Index.  
 
Figure 8. Kaplan-Meier curve for the development of severe liver disease, 
stratified on overweight status in study 4.
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5 DISCUSSION 
5.1 METHODOLOGICAL CONSIDERATIONS 
5.1.1 Study design 
When conducting medical research, one can basically perform either an experimental or an 
observational study. All studies in this thesis are examples of observational studies, using 
different methodologies. Study one and three are cross-sectional studies, where one group is 
compared to another, with no consideration of a temporal aspect. In contrast, study two and 
four are examples of cohort studies, where time is used as a parameter. In a cohort study, 
subjects that are or are not exposed to a potential harmful or beneficial factor (the exposure) 
are followed over time, and the outcome of interest is studied along the path. Differences 
between the exposed and unexposed groups are then calculated. 
5.1.2 Bias 
All research carries the risk of error, and medical research is no different. One differs 
between random errors, which can usually be handled by increasing the sample size of a 
studied population, and systematic errors, or bias (116). Bias must be dealt with either in the 
design of the study, or in its interpretation.  
5.1.2.1 Selection bias 
A selection bias is a danger to most medical studies. This can occur when there are 
differences between the exposed and the unexposed groups in a study in regard to how they 
were selected for the study, or if they stayed in the study for the entire study period or not. 
For example, if study subjects for a screening study are recruited by newspaper adds, 
individuals that are either at a higher risk for the studied outcome, or more concerned with 
their health might be over-represented, and thus introducing a bias to the study. Another 
example is the “healthy worker effect” (117). If studying the effect of an exposure on a 
specific outcome in workers, for instance the incidence of lower back pain in construction site 
workers and comparing this to the general public, a selection bias is introduced, as the general 
public is partly composed of persons that are too weak to work, and might have a higher risk 
of having lower back pain. 
5.1.2.2 Information bias / misclassification  
Misclassification can occur if there is an error in how study participants are classified as 
exposed or unexposed, or if they reach they study outcome or not. For example, persons 
drinking large amounts of alcohol might underreport their alcohol consumption, and be 
classified as non-drinkers. A specific form of misclassification is recall bias, where persons 
with a specific outcome, for instance myocardial infarction might recall their studied 
exposure, for instance past smoking history, different than persons without that specific 
outcome.  
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5.1.2.3 Confounding 
Confounding is very common in epidemiological studies, and must almost always be dealt 
with. Per definition, a confounder is a parameter that is both associated with the exposure and 
the outcome variable, but not a link in the causal pathway. A classic example of this is the 
risk of alcohol on development of lung cancer. Persons who drink alcohol often smoke, so if 
not taking smoking into account when studying this would most likely lead to inflated 
estimates on the risk of lung cancer in persons who drink alcohol. A schematic of 
confounding is presented in figure 9.  
 
 
 
 
 
 
 
Figure 9. Schematic of the confounding bias principle. The confounding variable is associated 
both with the exposure and the outcome, but is not a part of the causal pathway. 
5.1.3 Potential biases in the thesis 
There are several potential biases in the current thesis, which have been dealt with through 
different means. In study one and three, the main risk of bias is the recall bias of the LDH 
questionnaire. Study subjects might, knowingly or unknowingly, under- or over-report their 
past or current alcohol consumption. However, the LDH questionnaire has been validated and 
displays high test-retest reliability (103, 104). Also, removing subjects in study three with 
high PEth values should have reduced this type of bias. Selection bias should be minimal in 
study one, as PSC patients are rare, and nearly all patients in the Stockholm area were 
attending regular visits at our clinic at the time of the study. There is on the other hand a risk 
for selection bias in study three, as these patients were recruited from tertiary setting 
hospitals, and thus we might have selected cases with a higher disease activity than the 
common NAFLD patient. However, the results of the study should be generalizable to at least 
other university hospital patient groups.   
The same type of bias could be present in study two, that was also based on NAFLD patients 
that underwent liver biopsy. However, in that case all biopsies were performed due to 
increases in liver enzymes, and not of suspicion of manifest liver damage.  
Study four uses a different methodology than the previous three studies in that study 
participants were not selected from a larger group of potential study subjects, but instead we 
Exposure 
Confounder 
Outcome 
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had access to around 97% of the total Swedish male population in the relevant age categories 
at the time. This heavily reduces the risk for selection bias. Outcomes were selected to reduce 
the risk for detection bias as much as possible, by using only cases with severe liver disease 
that almost always leads to hospitalization or death and thus capture in the relevant registers.  
One limitation in study 4 is that it only includes men and the results may not be generalizable 
to women. There are previous studies indicating that a high BMI is a risk factor for future 
liver disease also in women. For example, Liu and co-workers found a high BMI a significant 
attributable factor for development of liver cirrhosis in women in the British Million Women 
Study, (118) but studies on young women are lacking. 
5.2 FINDINGS AND IMPLEMENTATIONS 
The role of low-grade alcohol consumption in patients with liver disease has not been studied 
extensively. It has, despite the lack of evidence, been the general consensus between 
clinicians that patients with any liver disease should not consume alcohol at all. Depending 
on the specific liver disease and the stage of disease, this may or may not be correct. For 
instance, low-grade alcohol consumption has been associated with a reduced risk of 
cardiovascular mortality (79). Patients with NAFLD have an increased risk for death in 
cardiovascular disease, so for instance consuming 1-2 drinks per day could actually be 
beneficial. On the other hand, alcohol has also been associated with increased risk for a 
number of malignancies, for instance breast and colon cancer (81, 82). Thus, an 
individualized approach regarding alcohol consumption should be sought when evaluating a 
patient with any liver disease.  
In study one, we evaluated a large cohort of patients with the rare disease PSC. Our main 
finding was that alcohol consumption of around one drink per day was not associated with 
higher stages of fibrosis, as evaluated by transient elastography or clinically evident cirrhosis. 
The use of the LDH questionnaire allowed us to track lifetime changes of alcohol 
consumption, and we found that PSC-patients with significant fibrosis had reduced their 
alcohol intake after the diagnosis of PSC, compared to patients with no significant fibrosis. 
This could reflect that patients with more severe disease feel less well and might try to reduce 
any additional damage to the liver. We found no difference in BMI between patients with and 
without significant fibrosis.  
PSC is an incurable, chronic liver disease, which is also associated with a reduced quality of 
life (119). Low-grade alcohol consumption, for instance a glass of wine per day, in patients 
with PSC should therefore be considered safe in patients who feel that this could improve 
their quality of life.  
The link between alcohol and liver disease has been known for a long time. As alcohol 
consumption almost invariably leads to fat accumulation in the liver through stimulation of de 
novo lipogenesis and reduced beta-oxidation (120), it was long thought that all patients with 
fatty liver were consuming large amounts of alcohol, and were not telling clinicians the truth 
about their alcohol habits. The first finding that patients who very credibly were not 
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alcoholics came from the Mayo clinic in 1980, where Ludwig et al showed a remarkably 
similar histological image to alcoholic steatohepatitis in obese patients with in many cases the 
metabolic syndrome, and named it non-alcoholic steatohepatitis (NASH) (121). Since then, 
the field of NAFLD research has exploded, with an exponential growth of published articles 
to match the increase in prevalence of obesity and NAFLD. The prognosis and natural history 
of NAFLD is heterogeneous and still poorly understood, with many potential factors able to 
influence the progression of the disease.  
In study two, we performed a study of markers for overall mortality in patients with NAFLD 
with the hitherto longest duration of follow-up ever presented. We show that the most 
important factor when evaluating future risk for mortality in a patient with NAFLD is the 
presence of significant fibrosis in the liver. We found no significant impact on mortality for 
the commonly used NAS scoring system, although a trend was noted for overall mortality 
and an increase in the risk of death due to HCC was found (table 2). Our findings were 
recently corroborated in another large follow-up study by the late Paul Angulo et al. This 
study showed no excess mortality in patients with a high NAS, but indicated that fibrosis 
stage was highly associated with mortality (122).  
The NAS is currently used as an endpoint in on-going phase III studies with thousands of 
patients, but if it cannot accurately predict mortality, it could be argued that other endpoints 
should be used instead, as a valid endpoint should measure how a patient feels, functions or 
survives either directly or through a proxy variable (123). Indeed, most of the current large 
clinical trials also use reduction of fibrosis stage as an endpoint, but it remains to be seen if 
this effect also has an impact on mortality. Apart from the extended follow-up in this study, 
there were several strengths. All patients were diagnosed with gold standard liver biopsy, 
there were very low loss to follow-up through population based registers, and even though the 
study was relatively small with 229 patients, this still represents one of the largest biopsy-
proven NAFLD cohorts worldwide. Nevertheless, results should be interpreted with the 
relatively small sample size in mind. 
Study three was similar to study one, in that we used the LDH questionnaire to examine the 
effect of lifetime alcohol consumption on disease severity in a chronic liver disease, this time 
looking at NAFLD. Our main finding was that an increase in alcohol intake, up to 13 units 
per week, was associated with a lower risk for having liver fibrosis, using an ordinal 
regression model. Conversely, subjects with PEth values over the established cut-off of 0.3 
μmol/L had an increased risk for liver fibrosis. This indicates that the risk profile for alcohol 
consumption on the risk of liver fibrosis has a J-like shape, with the lowest risk for persons 
drinking 1-2 units of alcohol per day. This is interestingly similar to the risk profile for 
alcohol consumption on the risk for cardiovascular disease. A number of studies have showed 
that regular alcohol consumption of around 1 unit per day in women and 1-2 per day in men 
seem to reduce cardiovascular morbidity and mortality (124-127). Patients with NAFLD and 
low stages of fibrosis (0-1) who consume alcohol in low to moderate amounts, i.e. below 13 
units per week, should not be advised to stop doing so. However, individuals with NAFLD 
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with concomitant risk factors for alcohol-associated malignancies should be given an 
individual risk profile.  
In study four, we found that overweight and a high BMI in late adolescence were associated 
with a higher risk for development of severe liver disease up to 39 years later. This risk was 
not affected by alcohol consumption, smoking or other potential confounders at baseline. 
Overweight persons had a 64% increased risk for development of severe liver disease, and a 
one unit increase in BMI (kg/m
2
) was associated with a 5% increased risk for this outcome. 
Overweight and obesity have been implicated as risk factors for liver disease in previous 
studies. For example, Ioannou et al showed that in persons without cirrhosis who drank little 
alcohol, obesity was associated with a 4.1 times increased risk of death in or hospitalization 
for liver disease after a mean of 12.9 years follow-up. That study was composed of older 
individuals (25-74 years of age), with a lower number of participants (N=11 465) and a 
shorter follow-up duration. Thus, our study is larger and we display a longer follow-up time, 
why our estimates should be more accurate. However, we had very few individuals with 
obesity in this study (0.8%), which is most likely why we see no significantly increased risk 
in this subpopulation.  
The strengths of this study are the large population-based cohort (n=44 248), very long 
follow-up time (39 years) and low (1%) loss to follow-up, which minimizes the risk of 
selection bias. Also, investigating men of a relatively low age as in the present study 
minimizes the risk for reverse causality regarding alcohol, since a long-term use of alcohol 
can also lead to overweight and obesity. We had access to detailed and credible baseline data 
regarding exposure status (height and weight) on almost the entire male population from the 
study period, as well as on a multitude of possible confounders such as alcohol consumption 
and use of narcotics. The national, population-based registers used for ascertaining outcome 
status are validated and a source of very high quality data. The use of liver decompensation 
and cirrhosis, which in almost all cases leads to hospitalization at some point, and liver-
related death as a joint outcome variable for severe liver disease, allowed us to minimize bias 
regarding the outcome status.  However, there were generally too few disease-specific 
outcomes, such as HCC for disease-specific analyses, which would require a larger cohort. 
For instance, overweight and obesity in early childhood has been shown to increase the risk 
of development of HCC in a large Danish cohort study with 285 884 subjects (128). 
The prevalence of overweight and obesity has risen sharply since the inclusion period in this 
study (129), although the high prevalence of obesity seems to have flattened out during the 
last decade, at least in the US (130). The mean time from conscription to development of 
severe liver disease in this study was long, on average 25 years. It is highly likely that there 
will be more cases of severe liver disease in the future, which could affect health policy 
decisions. The current study suggests that the increased risk of a high BMI for the 
development of severe liver disease later in life is present already from an early age. It is 
possible that this increased risk is caused by a longer exposure to being overweight, 
compared to becoming overweight or obese later in life, and that individuals with a longer 
  40 
history of being overweight have an increased risk of severe liver disease. This could have 
implications in the care of for example patients with NAFLD with a short versus a long 
duration of being overweight and should be explored in future studies. 
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6 CONCLUSIONS 
 
 Low grade alcohol consumption is not associated with significant fibrosis in PSC. 
 Low to moderate alcohol consumption, up to a maximum of 13 units per week, is 
associated with a lower fibrosis stage in NAFLD. 
 The most robust marker for overall and disease-specific mortality in NAFLD is 
fibrosis stage. Future clinical trials should use reduction of fibrosis stage as an 
endpoint.  
 A high BMI and overweight in late adolescence is associated with an increased risk 
for development of severe liver disease. Lifestyle modification in early adulthood 
including weight loss should be advised by health policies to reduce this risk. 
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7 FUTURE RESEARCH 
 
One previous study has suggested that alcohol consumption could be a risk factor for 
development of cholangiocarcinoma (CCC) in patients with PSC. Study subjects with PSC in 
this thesis consumed low amounts of alcohol, and the cross-sectional methodology did not 
allow us to study the impact of alcohol on the risk of CCC development. This should be 
explored in future studies, and we are planning to follow up this very well-defined cohort in a 
subsequent study in the near future, specifically looking at the risk of alcohol consumption on 
CCC development.  
 
The main finding of one of the studies in this thesis is that fibrosis is the strongest predictor 
for disease-specific mortality in NAFLD. However, this still requires liver biopsy, which is 
impractical to perform in the large group of subjects with possible NAFLD. Studies are 
needed to identify subjects at risk for development of fibrosis, preferably using non-invasive 
methodologies. Also, larger studies of subjects with NAFLD are required to identify which 
patients that have an increased risk for morbidity, such as development of diabetes mellitus 
type 2 and cardiovascular disease. The “magic bullet” in NAFLD research at the moment is 
identification of reliable, inexpensive and non-invasive biomarkers to identify subjects with 
NASH and fibrosis, respectively. This would allow researchers and industry to perform large 
clinical trials without the need for liver biopsy. We are currently investigating the effect of 
insulin-like binding protein 1 (IGF-BP1) as a marker of fibrosis in NAFLD, as well as 
participating in a study looking at performance of the Enhanced Liver Fibrosis (ELF) score in 
NAFLD.  
 
The finding that a high BMI in late adolescence is a risk factor for development of severe 
liver disease suggests that a longer duration of being overweight or obese is more harmful to 
the liver then becoming overweight later in life. This should be explored in future studies. 
Also, even with almost 45 000 study subjects, examining the effect of a high BMI on specific 
rare outcomes such as hepatocellular carcinoma was not possible in the current study. Future 
studies should include more study subjects, or a case-control methodology could be applied.  
 
In study three, we found that alcohol consumption is associated with lower stages of fibrosis 
in NAFLD, and that alcohol was associated with lower markers of inflammation, including 
TNF-alpha. Even though we had access to detailed data on possible confounders, due to the 
cross-sectional methodology, there could be residual confounding as well as other potential 
biases. A very interesting study would be to perform a randomized controlled study looking 
at low alcohol consumption versus abstinence in patients with established NAFLD.  
 
There is currently no established treatment for NAFLD, but there is considerable interest 
from the pharmacology industry, as the global revenue for a potential drug against NASH is 
estimated to 20-30 billion USD annually. At the moment, two large phase III studies are on-
going, but in phase II these drug candidates have either not shown impressive results or have 
caused problematic side-effects. We are currently exploring the possibility to perform a 
proof-of-concept study of a diet intervention to treat NAFLD, basically free of side-effects 
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and very inexpensive. This would allow patients with NAFLD to remain free of medications 
and most likely reduce the economic burden on society.  
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Leversjukdom är en allt vanligare orsak till död i världen. Traditionellt förknippar man 
framför allt leversjukdom med alkoholberoende, och många patienter med leversjukdom av 
annan anledning känner sig stigmatiserade på grund av detta. Tvärtemot denna myt så är den 
vanligaste leversjukdomen idag fettlever. Detta är nära kopplat till övervikt och höga nivåer 
av insulin i blodet, och innebär att fett inlagras i levern. Fettlever finns i nuläget hos 20-30% 
av den amerikanska befolkningen. Det är oklart vilka faktorer hos denna stora grupp som bäst 
förutsäger vilka som har en ökad risk att avlida. Man uppskattar att fettlever kommer vara 
den vanligaste orsaken till behov av levertransplantation inom en nära framtid. I Sverige är i 
nuläget en annan, ovanlig leversjukdom den vanligaste orsaken till behov av 
levertransplantation. Vid primär skleroserande kolangit (PSC) drabbas gallgångarna i och 
utanför levern av oklar anledning av sjukdom och skrumpnar ihop. Detta leder i slutändan till 
skrumplever och patienterna har en starkt ökad risk för cancer i lever och gallgångar.  
Det är oklart om en viss alkoholkonsumtion vid fettlever och PSC är säkert. Vi studerade 
därför detta hos två grupper av patienter med dessa sjukdomar. Vi fann att låggradig 
konsumtion av alkohol vid PSC inte var förenat med en svårare leversjukdom, och att 
låggradig alkohol konsumtion motsvarande max sju enheter per vecka är säkert vid PSC. För 
fettlever fann vi att alkoholkonsumtion, upp till max tretton enheter per vecka hade en 
skyddande effekt på utveckling av skrumplever. Däremot hade patienter som hade tecken till 
en högre alkoholkonsumtion än så också en högre risk för skrumplever.   
Vi undersökte i en studie vilka faktorer i levern som bäst kan förutsäga sjukdomsspecifik 
dödlighet. Vi använde oss av en unik grupp med 229 patienter med fettlever som hade följts 
över i medel 26 år och kopplade denna grupp till befintliga register över dödsfall och 
sjukhuskontakter. Vi fann att den viktigaste prognostiska faktorn för sjukdomsspecifik 
dödlighet var mängden av bindväv som fanns i levern.  
Övervikt och fetma har kopplats till en ökad risk att utveckla leversjukdom. Det är dock 
oklart om övervikt i sig självt är kopplat till utvecklingen av leversjukdom, eller om 
överviktiga t.ex. dricker mer alkohol än normalviktiga. För att studera detta analyserade vi 
data från cirka 45 000 män som genomgick mönstring under perioden 1969-70. Under 
mönstringen fick männen svara på detaljerade frågor om sin alkoholkonsumtion samt andra 
livsstilsmönster. Längd och vikt registrerades. Vi kopplade dessa data till samma register som 
i den föregående studien och fann att övervikt i sig, även efter att ha tagit alkoholkonsumtion 
i beaktande, var en oberoende riskfaktor för utveckling av svår leversjukdom upp till 39 år 
senare i livet. 
Sammanfattningsvis är resultaten från denna avhandling att det är säkert för patienter med 
PSC att dricka upp till en enhet alkohol per dag och att låggradig alkoholkonsumtion kan vara 
skyddande vid NAFLD. Vidare är den viktigaste riskfaktorn för död i NAFLD hur mycket 
bindväv det finns i levern, och övervikt är en oberoende riskfaktor för utveckling av svår 
leversjukdom.  
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